HOME >> BIOLOGY >> NEWS
New milestones on the path to conquering HIV drug resistance (AIDS)

NEW BRUNSWICK/PISCATAWAY, N.J. HIV is a moving target, unpredictably changing direction to elude anti-AIDS drugs, but researchers at Rutgers are clearly on the track of solutions to combat HIV drug resistance. Leading a multidisciplinary ensemble of colleagues, Rutgers Chemistry Professor Eddy Arnold recently reported on studies that revealed how some drugs may be getting the better of the virus' molecular defenses.

Reports in the May issues of Nature Structural & Molecular Biology and the Journal of Medicinal Chemistry propose answers to why it is relatively difficult for the AIDS virus to develop resistance to the drug, tenofovir, or the DAPY (diarylpyrimidine) family of compounds, and offers explanations of the mechanisms involved.

Tenofovir and the DAPY compounds are different types of reverse transcriptase (RT) inhibitors. RT is the enzyme or molecular machine the AIDS virus uses to replicate its genetic material. The two life-saving drugs approach the problem of drug resistance in different ways.

Arnold and his colleagues work on drugs that target HIV RT. "We try to understand how these drugs work and how they may be able to evade resistance mechanisms so that we can apply the information to the design of better drugs," said Arnold, a resident faculty member of the Center for Advanced Biotechnology and Medicine. The research institute is jointly administered by the University of Medicine and Dentistry of New Jersey and Rutgers, The State University of New Jersey.

Since 1987, Arnold has collaborated with Stephen Hughes of the National Cancer Institute's Cancer Research and Development Center at Frederick, Md., constituting what Arnold calls "an inseparable team." Hughes is providing the biochemical analysis of the problem in conjunction with Arnold's X-ray crystallography a method by which X-ray diffraction patterns obtained from crystals are used to map the three-dimensional atomic structure of large molecules.

"W
'"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 x652
Rutgers, the State University of New Jersey
29-Jun-2004


Page: 1 2 3

Related biology news :

1. New reserach shows promise in conquering ulcer-causing H. pylori
2. Master of antimalarial resistance
3. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
4. Evolvability could be a driving force in drug resistance
5. Insecticide resistance: A constraint on evolutionary change
6. New drug shows promise against Gleevec resistance in mice
7. Study investigates breast cancer resistance to tamoxifen and possible way to reverse it
8. Antibiotic resistance risk from triclosan questioned
9. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
10. Researchers string together players in pesticide resistance orchestra
11. Chicken litter harbors agents that generate antibiotic multi-resistance, according to UGA study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New milestones the path conquering HIV drug resistance AIDS

(Date:3/19/2015)... OXFORD, Conn. , March 19, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce market, ... featured in a news clip that aired this week on ... http://www.myfoxdc.com/ ) . In a segment "The Next ... smart wallet ,a new way to pay, and ,a really ...
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
(Date:3/30/2015)... /CNW/ - A new national Labour Market Information (LMI) ... profiles of new graduates entering the biotech sector. The ... for New Grads in Biotech," is sponsored in part ... (Rx&D) and features data collected from new graduates that ... from 2013 to 2015. Among the interesting ...
(Date:3/30/2015)... N.J. , March 30, 2015  Naldemedine, ... under development by Shionogi & Co., Ltd., met ... III study (COMPOSE I) for the treatment of ... non-cancer pain receiving opioid therapy. Study results showed ... statistically significantly improved the frequency of spontaneous bowel ...
(Date:3/29/2015)... , March 29, 2015 Caris ... important study data showing the presence of ... gynecologic cancer samples. Using Caris Molecular Intelligence®, ... researchers identified expression of programmed cell death ... of histology while its ligand (PD-L1) expression ...
(Date:3/27/2015)... March 27, 2015  Neogen Corporation (NASDAQ: NEOG ... a prearranged trading plan in accordance with Securities and ... and CEO of Neogen Corporation, is a minority owner ... common stock. Herbert does not have control ... The filing is only for a portion of the ...
Breaking Biology Technology:New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Neogen CEO adopts 10b5-1 Trading Plan 2
Cached News: